FIB 918
Alternative Names: FIB-918Latest Information Update: 12 Mar 2024
At a glance
- Originator Fibrocor Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Discoidin domain receptor modulators; Integrin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hereditary nephritis
Most Recent Events
- 05 Mar 2024 Fibrocor Therapeutics and McQuade Center for Strategic Research and Development agree to co-promote and co-develop FIB 918 for Hereditary nephritis
- 05 Mar 2024 Preclinical trials in Hereditary nephritis in Canada (Parenteral), prior to March 2024
- 05 Mar 2024 Fibrocor Therapeutics announces intention to submit IND application for Hereditary nephritis